Skip to main content

Gene and Cell Therapy Experts and Information for Media

Gene therapy treats disease by replacing a patient’s defective gene with a healthy one, and CAR T-cell therapy treatment genetically reprograms an individual’s own T cells to target and destroy that patient’s cancer cells. St. Jude is developing innovative gene therapies and approaches for patients with blood diseases, immune disorders and other conditions.

Our clinicians and researchers offer credible information, hands-on expertise and clinical insight on the most recent news and discoveries in gene therapy and cell therapy research.

Learn more about gene therapy and CAR T-cell research at St. Jude.

The following experts are available to offer credible information, hands-on expertise and clinical insight on gene and cell therapy.

To schedule interviews or speak with one of our experts, email or contact one of our media relations staff.

Contact Media Relations

Gene and Cell Therapy Experts

  • Andrew M. Davidoff, MD

    Andrew Davidoff, MD, is Surgery chair and Surgical Research director at St. Jude Children's Research Hospital. Davidoff researches new strategies to treat neuroblastoma and other solid tumors. Currently, he can be contacted about his work aimed to inhibit the formation of new, tumor-feeding blood vessels, as wells as his efforts to use gene therapy in the treatment of hemophilia.

  • Stephen Gottschalk, MD

    Stephen Gottschalk, MD, is the Bone Marrow Transplantation and Cellular Therapy chair at St. Jude Children's Research Hospital. His research focuses on cancer immunotherapy, cell therapy and stem cell transplantation. Gottschalk leads a team of clinical and scientific researchers who are conducting clinical studies with highly specific T cells for patients with blood cancers and severe combined immunodeficiency (SCID), as well as brain and other solid tumors. The Gottschalk laboratory is focused on Epstein-Barr virus (EBV)-specific T cells for the treatment of EBV-associated cancers, and the use of genetically modified T cells for cancer immunotherapy. Gottschalk can also speak on the successful cure, pioneered at St. Jude, of X-linked severe combined immunodeficiency disease (SCID), also known as Bubble Boy Disease.

  • Ellis J. Neufeld, MD, PhD

    Ellis Neufeld, MD, PhD, is physician-in-chief and clinical director at St. Jude Children's Research Hospital. He oversees the academic clinical departments and all clinical operations, with a focused effort to increase the number of cancer patients treated on campus and around the world. Neufeld can provide information associated with his clinical and research interests that center on nonmalignant hematology, including ITP, thalassemia, transfusional iron overload, hemophilia and thrombosis, as well as patient-oriented studies.